See the Results

KESIMPTA® impacted RMS disease activity

Header
 

Dramatic results that speak for themselves.

KESIMPTA was proven effective in reducing the relapsing MS activity you see (relapses and disability progression), and the activity you don’t (lesions).

KESIMPTA went head-to-head with AUBAGIO® in 2 studies. Over 1,800 people aged 18-55 years with relapsing MS participated. All of them had a relapse or saw activity on an MRI in the last 1–2 years leading up to the studies. Each person received KESIMPTA or AUBAGIO for up to 30 months.

Not only are relapses unpredictable, but they interrupt your day-to-day.

line break dashed

Knowing disability could get worse can be top of mind for people with relapsing MS.

*This was based on whether or not disability progression was still present 3 and 6 months after disability symptoms started.
line break dashed

If these lesions show up, it may mean your relapsing MS is more active than you’re aware of.

line break dashed

These lesions, both old and new, show the impact relapsing MS has on the brain.

line
text callout teal
You've seen what KESIMPTA can do.
Start the convo with your doctor to see if it's right for you.
Gd+=gadolinium-enhancing; MS=multiple sclerosis; RMS=relapsing multiple sclerosis
AUBAGIO (teriflunomide), an oral relapsing MS treatment, is a registered trademark of Sanofi and Genzyme.